Clover Health's earnings call highlighted significant membership and revenue growth, sustained profitability, and promising technological advancements, although challenges such as elevated costs and a GAAP net loss were noted. The outlook for 2026 remains positive with expected financial tailwinds.

Company Guidance

In the second quarter of 2025, Clover Health reported strong financial performance and strategic progress. The company achieved a 32% year-over-year increase in Medicare Advantage membership, reaching over 106,000 members. This growth contributed to a 34% rise in insurance revenue, totaling $470 million for the quarter. Clover Health maintained adjusted EBITDA profitability, with $70 million reported for the quarter and $43 million year-to-date. Despite elevated costs in Part D and supplemental benefits, the company adjusted its full-year insurance MLR guidance to 88.5%-89.5%. The company also improved its adjusted SG&A as a percentage of total revenue to 17%, showcasing enhanced operational efficiencies. Looking ahead, Clover Health anticipates continued membership growth and profitability in 2026, bolstered by a transition to a 4-star payment year and strategic investments in its technology-driven care model.

Strong Membership and Revenue Growth

Clover Health saw a 32% increase in Medicare Advantage membership year-over-year, reaching over 106,000 members, and a 34% increase in insurance revenue to $470 million in the second quarter.

Sustained Adjusted EBITDA Profitability

The company maintained its adjusted EBITDA profitability through the first half of 2025, with $70 million in adjusted EBITDA and adjusted net income for the second quarter.

Improved SG&A Efficiency

Adjusted SG&A as a percentage of total revenues improved to 17% this quarter, a 280 basis point improvement year-over-year, demonstrating operating leverage amidst strong growth.

Technological Advancements with Clover Assistant

The Clover Assistant technology model is showing success, with a clinical white paper indicating a correlation with 15% fewer hospitalizations and 18% fewer readmissions for COPD.

Positive Outlook for 2026

The company anticipates a 4-star payment year in 2026, which is expected to provide financial tailwinds and support further growth and profitability.

Clover Health Investments (CLOV) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CLOV Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	-0.04 / -	-0.02	―	―	―
Aug 05, 2025	2025 (Q2)	>-0.01 / -0.02	0.01	-300.00% (-0.03)
May 06, 2025	2025 (Q1)	-0.04 / 0.05	-0.05	206.00% (+0.10)
Feb 27, 2025	2024 (Q4)	-0.07 / -0.04	-0.146	72.60% (+0.11)
Nov 06, 2024	2024 (Q3)	-0.04 / -0.02	-0.086	76.74% (+0.07)
Aug 05, 2024	2024 (Q2)	-0.05 / 0.01	-0.06	116.67% (+0.07)
May 07, 2024	2024 (Q1)	-0.07 / -0.05	-0.152	67.11% (+0.10)
Mar 12, 2024	2023 (Q4)	-0.14 / -0.15	-0.176	17.05% (+0.03)
Nov 06, 2023	2023 (Q3)	-0.11 / -0.09	-0.158	45.57% (+0.07)
Aug 08, 2023	2023 (Q2)	-0.14 / -0.06	-0.219	72.60% (+0.16)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CLOV Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$2.85	$2.26	-20.70%
May 06, 2025	$3.35	$3.77	+12.54%
Feb 27, 2025	$4.14	$3.97	-4.11%
Nov 06, 2024	$4.35	$3.67	-15.63%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.